X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LUT014 is a novel B-Raf inhibitor, small molecule drug which is applied topically on the skin. It is being evaluated for the treatment of EGFRI-Induced Acneiform Rash.
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
The award will allow for the completion of Investigational New Drug enabling studies. Specifically, the funds will be utilized for the manufacturing of LUT017 active pharmaceutical ingredient and the final formulated drug product (LUT017 gel) to supply the proposed studies.
Lead Product(s): LUT017
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LUT017
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: California Institute of Regenerative Medicine
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 24, 2022
Details:
LUT-RD (LUT014) is designed to balance the destruction of cells in the basal layer of the skin resulting from radiation, by enhancing cell proliferation, thus potentially reversing the effects of radiation dermatitis.
Lead Product(s): LUT-014
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: LUT-RD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
The trial will evaluate the efficacy and safety of two strengths of LUT014 Gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo, in patients with mCRC who develop Grade 2 EGFR inhibitor-induced acneiform lesions, with a 4-week follow up period.
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2021
Details:
ALLO-501A, a next-generation anti-CD19 AlloCAR T , eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure.
Lead Product(s): LUT-014
Therapeutic Area: Dermatology Product Name: LUT014
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
